|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 212.50 CHF | +1.43% |
|
+3.41% | +20.74% |
| Dec. 08 | HBM Healthcare Investments Set to Receive Payments from Portfolio Company Sale | MT |
| Dec. 08 | Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics | RE |
Published on 05/13/2025
HBM Healthcare Investments AG reported earnings results for the full year ended March 31, 2025. For the full year, the company reported revenue was CHF 22.32 million compared to CHF 2.98 million a year ago. Net income was CHF 18.54 million compared to net loss of CHF 1.08 million a year ago.
Basic earnings per share from continuing operations was CHF 2.72 compared to basic loss per share from continuing operations of CHF 0.16 a year ago.
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Select your edition
All financial news and data tailored to specific country editions
